Jagiellonian University Medical College, Faculty of Medicine, Chair of Microbiology, Department of Molecular Medical Microbiology, Krakow, Poland.
Jagiellonian University Medical College, Faculty of Health Sciences, Institute of Public Health, Department of Health Promotion, Krakow, Poland.
Adv Med Sci. 2020 Sep;65(2):348-353. doi: 10.1016/j.advms.2020.06.003. Epub 2020 Jun 23.
The aim of this study was to determine quantitative changes in selected species of bacteria (Bacteroides fragilis, Lactobacillus fermentum, Lactobacillus rhamnosus, Serratia marcescens) in the stool of patients with Crohn's disease (CD) in the course of induction treatment with exclusive enteral nutrition (EEN) or anti-tumor necrosis factor alpha (Infliximab, IFX) vs. healthy controls (HC).
MATERIALS/METHODS: DNA was isolated from stool samples of CD (n = 122) and HC (n = 17), and quantitative real-time Polymerase Chain Reaction (qPCR) was applied. In both treatment groups, the first stool sample was taken before the start of treatment, and the second 4 weeks after its end: in EEN (n = 48; age (mean; SD) 13.35 ± 3.09 years) and IFX groups (n = 13; age (mean; SD) 13.09 ± 3.76 years).
The only species that showed a statistically significant difference between the two groups of patients before any therapeutic intervention was L. fermentum. Moreover, its number increased after completion of EEN and differed significantly when compared with the HC. In the IFX group the number of L. fermentum decreased during the therapy but was significantly higher than in the HC. The number of S. marcescens in the EEN group was significantly lower than in the controls both before and after EEN.
The implemented treatment (EEN or IFX) modifies the microbiome in CD patients, but does not make it become the same as in HC.
本研究旨在确定在接受肠内营养（EEN）或抗肿瘤坏死因子-α（英夫利昔单抗，IFX）诱导治疗的克罗恩病（CD）患者粪便中脆弱拟杆菌、发酵乳杆菌、鼠李糖乳杆菌、粘质沙雷氏菌等特定细菌种属的数量变化，并与健康对照（HC）进行比较。
材料/方法：从 CD（n=122）和 HC（n=17）患者的粪便样本中提取 DNA，应用实时聚合酶链反应（qPCR）。在两组治疗中，第一份粪便样本在治疗开始前采集，第二份在治疗结束后 4 周采集：EEN 组（n=48；年龄（平均值；标准差）13.35±3.09 岁）和 IFX 组（n=13；年龄（平均值；标准差）13.09±3.76 岁）。
在任何治疗干预之前，只有发酵乳杆菌是两组患者之间具有统计学显著差异的物种。此外，EEN 治疗后其数量增加，与 HC 相比差异显著。IFX 组在治疗期间发酵乳杆菌数量减少，但仍显著高于 HC。EEN 组的粘质沙雷氏菌数量在治疗前和治疗后均明显低于对照组。
实施的治疗（EEN 或 IFX）改变了 CD 患者的微生物组，但并未使其与 HC 相同。
